Medical Device Sales Commission Structure: What Reps Actually Earn

A district manager I know at an orthopedic implant company was explaining commission to a new hire last fall. The new rep was a few months out of a B2B software background, reasonably sharp, had done his homework on base salary ranges, and was satisfied with what he'd been offered. Then the DM walked him through the quota structure, the commission tiers, and the territory override clause, and the new rep's expression shifted — somewhere between surprised and unsettled.

"So if I hit 85% of quota, I'm at a lower rate for the whole year?" he asked.

The DM nodded.

"Even on the revenue I did generate?"

"Especially on that."

The rep had optimized for the base and hadn't understood what he was agreeing to on the variable side. He stayed with the company and figured it out. But it took him most of his first year to mentally recalibrate from the software sales comp model he was used to — where deals close and commissions follow — to the device model, where territory relationships are built over 12 to 18 months and the payout structure rewards patience and account depth in ways that aren't obvious until you've lived through a fiscal year.

Device sales compensation is not complicated once you understand the structure. The structure just isn't always explained clearly up front.

How device compensation is actually built

Medical device sales compensation has four components, and the mix varies significantly by segment and company. Understanding how they interact is more useful than knowing any single number.

Base salary. Base salaries in medical device sales range broadly — in my experience across placements in orthopedics, cardiovascular, and surgical robotics, entry-level device reps typically start between $48k and $72k. Mid-tenure reps with established territories in complex capital equipment often see bases of $85k to $120k. These aren't precise averages; they're ranges from a relatively modest set of data points, maybe 30 to 40 placements over the past two years. The variance within any segment is high enough that a single number isn't particularly useful.

The base isn't the ceiling or even the floor of what a rep takes home. It's more like the foundation — the number that tells you how the company weights stability versus upside in their comp philosophy.

Commission. Commission in device is almost universally structured as a percentage of revenue, not a flat per-unit amount. The percentage varies by product margin, by company philosophy, and by how the commission tiers are set. Commission rates on lower-margin disposables might run 2% to 5% of revenue. On higher-margin capital equipment, rates of 6% to 10% on revenue above quota are not unusual.

The tier structure is where it gets interesting. Most device companies set a threshold — often 80% to 85% of quota — below which the commission rate drops. Some companies reduce the rate only on revenue below threshold. Others apply the reduced rate retroactively across all revenue for the year if you finish below threshold. That retroactive structure is the one that produces the DM conversation I described above. Understand which model applies before you accept an offer.

Draw. Many device companies, particularly for new hires covering territories that need to be built from scratch, offer a draw against future commissions in the first six to twelve months. A draw is essentially an advance on earnings — the company covers income while the rep establishes accounts, with the expectation that commissions earned over time will repay the advance and eventually exceed it.

Draws are either recoverable (meaning you owe the company money if your commissions don't cover the draw during the draw period) or non-recoverable (meaning you keep the draw regardless of commission performance). Non-recoverable draws are better for the rep; recoverable draws shift more risk onto them. Which one a company offers reflects how confident they are in their territory and their training.

Override commissions. In territories where the primary rep sells through distributors or dealer networks, override commissions compensate the rep for managing those channel relationships even when they don't close deals directly. Override rates are typically lower than direct commission rates — often in the 1% to 3% range — but in high-volume territories with active distribution partners, they can represent a meaningful portion of total earnings.

Note: These ranges reflect a limited dataset and are meant to orient, not benchmark. Actual figures vary significantly by company, geography, and product maturity.

What's actually negotiable

The standard wisdom is that base salary is negotiable and commission structure isn't. This is partially true and partially outdated.

For experienced reps joining with an established book of relationships in a specific geography, base salary is often quite negotiable — companies know they're buying account access, not just a resume. I've seen reps with proven track records in a specific territory negotiate bases 15% to 22% above the posted range.

Commission rates on established products are harder to move, but a few things are negotiable even there. The quota threshold below which the reduced rate kicks in is sometimes adjustable, particularly for reps inheriting difficult territories. The draw structure — specifically whether the draw is recoverable — is frequently negotiable if the rep can make the case that the territory needs longer than average to build. Territory exclusivity provisions, which determine whether you're competing with company direct reps or dealer networks in your geography, matter for override commission calculations and are worth clarifying explicitly.

The most important thing that's often overlooked in compensation negotiations: get the quota assignment methodology in writing before you accept an offer. Quota should be set based on documented territory potential — historical revenue, prescriber density, account mix — not on a centralized model that applies the same growth expectation to every territory regardless of local conditions. A poorly set quota can make a strong commission structure meaningless.

The independent contractor model

For reps considering a 1099 arrangement rather than a W-2 position, the compensation structure is fundamentally different in ways that are sometimes better and sometimes worse depending on what you're optimizing for.

Independent contractors in medical device typically work on a higher commission rate — often 8% to 15% of revenue they generate — in exchange for not receiving a base salary, benefits, or expense reimbursement from the company. The trade is stability for upside: a successful independent rep working a mature territory in orthopedics, say, can out-earn a W-2 rep with similar accounts by a meaningful margin. A rep building a new territory from scratch, where the first year is primarily relationship establishment and revenue is thin, faces a tougher runway without a base to cover living expenses.

The tax picture is also more complex as a 1099 contractor — self-employment taxes, quarterly estimated payments, and business expense tracking add overhead that W-2 employment absorbs automatically. The gross commission number is higher; the net number requires more discipline to manage.

That said, for experienced reps with established relationships who want to control their own time and potentially carry complementary non-competing lines, the contractor model has real advantages that a W-2 structure can't offer.